PEARL RIVER, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/convention name together with its second quarter 2023 replace and monetary outcomes on Tuesday, August 8 at 4:30 p.m. ET.
To take part within the Webcast, please use the next registration hyperlink:
For those who register for the Webcast, you’ll have the chance to submit a written query for the Q&A portion of the presentation. After you may have registered, you’ll obtain a affirmation e-mail with the Webcast particulars. On the day of the Webcast, you’ll obtain an e-mail 2 hours previous to the beginning of the Webcast with the hyperlink to affix. The presentation might be obtainable on the Buyers part of www.acorda.com.
A replay of the decision might be obtainable from 8:30 p.m. ET on August 8, 2023, till 11:59 p.m. ET on September 7, 2023. To entry the replay, please dial 1 866 813 9403 (home) or +1 929 458 6194 (worldwide); entry code 649308. The archived webcast might be obtainable within the Investor Relations part of the Acorda web site at www.acorda.com.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to revive operate and enhance the lives of individuals with neurological issues. INBRIJA® (levodopa inhalation powder) is authorized for intermittent remedy of OFF episodes in adults with Parkinson’s illness handled with carbidopa/levodopa. INBRIJA will not be for use by sufferers who take or have taken a nonselective monoamine oxidase inhibitor reminiscent of phenelzine or tranylcypromine throughout the final two weeks. INBRIJA makes use of Acorda’s progressive ARCUS® pulmonary supply system, a know-how platform designed to ship remedy by way of inhalation. Acorda additionally markets the branded AMPYRA® (dalfampridine) Prolonged Launch Tablets, 10 mg.
Ahead-Wanting Statements
This press launch consists of forward-looking statements. All statements, aside from statements of historic details, concerning administration’s expectations, beliefs, objectives, plans or prospects needs to be thought-about forward-looking. These statements are topic to dangers and uncertainties that might trigger precise outcomes to vary materially, together with: we could not have the ability to efficiently market INBRIJA, AMPYRA or another merchandise beneath growth; the COVID-19 pandemic, together with associated restrictions on in-person interactions and journey, and the potential for sickness, quarantines and vaccine mandates affecting our administration, workers or consultants or people who work for different firms we depend on, may have a cloth opposed impact on our enterprise operations or product gross sales; our capacity to draw and retain key administration and different personnel, or keep entry to skilled advisors; our capacity to lift further funds to finance our operations, repay excellent indebtedness or fulfill different obligations, and our capacity to regulate our prices or scale back deliberate expenditures; the reverse inventory break up and its influence on the buying and selling of our frequent inventory; dangers associated to the profitable implementation of our marketing strategy, together with the accuracy of its key assumptions; dangers associated to our company restructurings, together with our capacity to outsource sure operations, notice anticipated price financial savings and keep the workforce wanted for continued operations; dangers related to complicated, regulated manufacturing processes for prescribed drugs, which may have an effect on whether or not we’ve got enough industrial provide of INBRIJA or AMPYRA to fulfill market demand; our reliance on third-party producers for the well timed manufacturing of economic provides of INBRIJA and AMPYRA; third-party payers (together with governmental businesses) could not reimburse for using INBRIJA or AMPYRA at acceptable charges or in any respect and will impose restrictive prior authorization necessities that restrict or block prescriptions; reliance on collaborators and distributors to commercialize INBRIJA and AMPYRA exterior the U.S.; our capacity to fulfill our obligations to distributors and collaboration companions exterior the U.S. referring to commercialization and provide of INBRIJA and AMPYRA; competitors for INBRIJA and AMPYRA, together with growing competitors and accompanying lack of revenues within the U.S. from generic variations of AMPYRA (dalfampridine) following our lack of patent exclusivity; the power to appreciate the advantages anticipated from acquisitions as a result of, amongst different causes, acquired growth applications are usually topic to all of the dangers inherent within the drug growth course of and our information of the dangers particularly related to acquired applications usually improves over time; the danger of unfavorable outcomes from future research of INBRIJA (levodopa inhalation powder) or from different analysis and growth applications, or another acquired or in-licensed applications; the prevalence of opposed security occasions with our merchandise; the end result (by judgment or settlement) and prices of authorized, administrative or regulatory proceedings, investigations or inspections, together with, with out limitation, collective, consultant or class-action litigation; failure to guard our mental property, to defend towards the mental property claims of others or to acquire third-party mental property licenses wanted for the commercialization of our merchandise; and failure to adjust to regulatory necessities may lead to opposed motion by regulatory businesses.
These and different dangers are described in higher element in our filings with the Securities and Alternate Fee. We could not really obtain the objectives or plans described in our forward-looking statements, and traders shouldn’t place undue reliance on these statements. Ahead-looking statements made on this press launch are made solely as of the date hereof, and we disclaim any intent or obligation to replace any forward-looking statements because of developments occurring after the date of this press launch, besides as could also be required by regulation.